John Gildea
John Gildea is a cell biology researcher who leads scientific work at Mara Labs. He discusses cellular signaling and the development of stabilized sulforaphane products.
Statements
20 statements
John Gildea describes a pilot study that detected sulforaphane metabolites in breast tissue after participants drank a broccoli sprout preparation before surgery.
John Gildea contrasts concentrations used in cell experiments with what he expects after taking curcumin orally, saying the higher experimental concentrations are hard to reach.
John Gildea describes early research by Paul Talalay’s group. The researchers isolated sulforaphane from broccoli and measured induction of a phase II enzyme in a cell assay. The study measured enzyme activity in the lab.
John Gildea contrasts redox changes during exercise with what he describes as sulforaphane acting directly on reactive cysteines in KEAP1.
John Gildea says his company supplied sulforaphane to researchers studying an exercise question. He says he does not know the answer yet.
John Gildea suggests taking sulforaphane in the morning and at night because he believes those times line up with NRF2 activity in the circadian cycle.
John Gildea says sulforaphane would lower two urinary markers he describes as reflecting oxidative stress, one for DNA and one for RNA.
John Gildea says his NRF2 assay gave similar results in two conditions and concludes that the surrounding food may have little effect on sulforaphane in that assay.
John Gildea says he thinks curcumin activates NRF2 through a pathway involving PKC delta, allowing NRF2 to enter the nucleus.
John Gildea says quercetin inhibits the proteasome and describes the substances in his lineup as acting on NRF2.
John Gildea describes berberine as activating AMPK and connects that pathway to GSK3 beta and nuclear export.
John Gildea cautions that activating the NRF2 pathway in cell culture with compounds such as EGCG or quercetin does not show that the same effect occurs after taking them. Exposure at the cell can differ from the concentrations used in lab experiments.
John Gildea says his company favors its sulforaphane product because he believes it reaches cells at a concentration that can act on several targets.
John Gildea claims that combining curcumin with sulforaphane could have complementary effects on NRF2 and NF-κB signaling.
John Gildea describes a hypothesis in which sulforaphane or PEITC temporarily lowers glutathione and affects cells already under oxidative stress.
John Gildea says that in the work he describes, they found microplastics in sweat and urine, while the signal he attributes to sulforaphane appeared in feces.
John Gildea proposes a mechanism involving cysteine transport in his discussion of glutathione.
John Gildea discusses conjugation and speculates about how sulforaphane could relate to what people feel after fasting.
John Gildea discusses berberine and a proposed mechanism involving c-Myc.
John Gildea recounts a study that he describes as giving participants a broccoli-sprout beverage over 12 weeks.
